Last reviewed · How we verify
NCT03515356
Exercise to Reduce Chemotherapy-Induced Peripheral Neuropathy
NA trial testing MI-Walk Intervention in Gastrointestinal Cancer in 54 participants. Completed in 24 June 2019.
24 June 2019
Quick facts
| Lead sponsor | University of Michigan Rogel Cancer Center |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | supportive care |
| Enrollment | 54 |
| Start date | 13 June 2018 |
| Primary completion | 24 June 2019 |
| Estimated completion | 24 June 2019 |
| Sites | 7 locations across United States |
Drugs / interventions tested
- MI-Walk Intervention
- Physical Activity Education Pamphlet
Conditions studied
- Gastrointestinal Cancer — all drugs for Gastrointestinal Cancer →
- Colorectal Cancer — all drugs for Colorectal Cancer →
- Pancreatic Cancer — all drugs for Pancreatic Cancer →
- Gastric Cancer — all drugs for Gastric Cancer →
Sponsor
University of Michigan Rogel Cancer Center
Who can join
18 and older, any sex, with Gastrointestinal Cancer or Colorectal Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This randomized, controlled, pilot experiment will evaluate the effects of an aerobic walking intervention on OIPN (oxaliplatin-induced peripheral neuropathy) in patients with gastrointestinal (GI) cancer who are already prescribed oxaliplatin (85 mg/m2 every other week for at least six cycles) by their oncologists. Oxaliplatin is a standard chemotherapy treatment for invasive GI cancers that causes OIPN in 85-95% of patients.
Publications & conference data
6 peer-reviewed publications reference this trial (live from Europe PMC):
-
Effect of exercise on colorectal cancer prevention and treatment.
Oruç Z, Kaplan MA. · · 2019 · cited 72× · PMID 31139306 · DOI 10.4251/wjgo.v11.i5.348 -
A review of physical activity in pancreatic ductal adenocarcinoma: Epidemiology, intervention, animal models, and clinical trials.
Hsueh HY, Pita-Grisanti V, Gumpper-Fedus K, Lahooti A, et al · · 2022 · cited 17× · PMID 34750076 · DOI 10.1016/j.pan.2021.10.004 -
Interventions for promoting physical activity in people with neuromuscular disease.
Jones K, Hawke F, Newman J, Miller JA, et al · · 2021 · cited 16× · PMID 34027632 · DOI 10.1002/14651858.cd013544.pub2 -
Physiotherapy for people with painful peripheral neuropathies: a narrative review of its efficacy and safety.
Jesson T, Runge N, Schmid AB. · · 2020 · cited 12× · PMID 33490836 · DOI 10.1097/pr9.0000000000000834 -
Emerging Approaches for the Management of Chemotherapy-Induced Peripheral Neuropathy (CIPN): Therapeutic Potential of the C5a/C5aR Axis.
Spera MC, Cesta MC, Zippoli M, Varrassi G, et al · · 2022 · cited 10× · PMID 36098939 · DOI 10.1007/s40122-022-00431-8 -
Home-based aerobic exercise feasibility in oxaliplatin-receiving newly-diagnosed cancer survivors.
Kanzawa-Lee GA, Larson JL, Resnicow K, Ploutz-Snyder R, et al · · 2024 · cited 2× · PMID 38954929 · DOI 10.1016/j.ejon.2024.102649
Verify or expand the search:
- PubMed search for NCT03515356
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Gastrointestinal Cancer
Currently open trials in the same condition.
- NCT07524114 — Study of High-Precision Evaluation of Molecular ResiduaL Disease Through a PlatfOrm for Cancer TracKing and Interception · recruiting
- NCT07003061 — Sarcopenia and Neuromuscular Block in Gastrointestinal Cancer Surgery · recruiting
- NCT06936878 — BOLSTER: Learning New Skills to Thrive · NA · recruiting
- NCT06864169 — A Study of Raludotatug Deruxtecan (R-DXd) in People With Gastrointestinal Cancers (MK-5909-005) · Phase 2 · active not recruiting
- NCT07056777 — Evaluation of the Preliminary Efficacy and Safety of DR30206 in Combination With Standard Therapy in Patients With Gastr · Phase 1, PHASE2 · recruiting
Other University of Michigan Rogel Cancer Center trials
Trials by the same sponsor.
- NCT06914479 — Virus-Based Gene Therapy (AdV-HSV1-TK and AdV-Flt3L) in Combination With Valacyclovir for the Treatment of Pediatric and · Phase 1 · recruiting
- NCT07481344 — SunBeast: Evaluating UV Protective Behaviors and Education Interventions Among Ultrarunners · NA · not yet recruiting
- NCT07526545 — Urine Prostate Screening Integrated With MRI for Early Detection of Prostate Cancer, UPRISE Trial · NA · not yet recruiting
- NCT07443943 — A Dietary Supplement (Resistant Potato Starch) for Reducing Musculoskeletal Symptoms in Individuals Planning to Receive · Phase 2 · recruiting
- NCT07365007 — A Virtually Delivered Diet Intervention (LASO-3) for the Improvement of Chemotherapy-Induced Peripheral Neuropathy in Ca · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03515356 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Michigan Rogel Cancer Center
- Last refreshed: 9 March 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03515356.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing